Home Healthcare Medical Devices India Cardiac Resynchronization Therapy (CRT) Market

India Cardiac Resynchronization Therapy (CRT) Market Size, Share & Trends Analysis Report By Product (CRT-Defibrillator, CRT-Pacemaker), By End User (Hospitals, Cardiac Centers, Ambulatory Surgical Centers, Other End Users) and Forecasts, 2026-2034

Last Updated: August 24, 2026 | Author: Debashree Bora | Format:
India Cardiac Resynchronization Therapy (CRT) Market Size

Download a Free Sample To learn more about this report,

Market Overview

The India Cardiac Resynchronization Therapy (CRT) Market size was valued at USD 306 million in 2025 and is projected to grow from USD 332 million in 2026 to reach USD 792 million by 2034, growing at a CAGR of 10.12% during the forecast period 2026–2034.

Cardiac resynchronization therapy (CRT) is a treatment that assists the heart in beating at the correct rate. It employs a pacemaker to restore the heartbeat's normal timing pattern. The CRT pacemaker coordinates the synchronization of the heart's upper (atria) and lower (ventricles) chambers. It also regulates the synchronization between the heart's left and right sides.

The market for cardiac resynchronization therapy (CRT) was estimated to be worth USD 5.85 billion in 2021. One of the major trends accelerating market expansion is the rapid advancement of technology. The market is expanding due to sedentary lifestyle adoption, an aging population, and increased cardiovascular disease prevalence.

Highlights

  • CRT-D dominates the market by Product. 
  • Hospitals dominate the market by End-User.

Market Dynamics

India Cardiac Resynchronization Therapy (crt) Market Drivers

High Prevalence of Cardiac Diseases

Heart failure and arrhythmias are two of the major cardiovascular illnesses in India. There is a demand for effective treatment alternatives like CRT because of the increasing prevalence of these illnesses, which is linked to factors including sedentary behavior, lifestyle changes, and rising obesity rates. The demand for cutting-edge cardiac therapy drives the adoption of CRT devices in the Indian market.

Increasing Aging Population

With a growing older population, India is experiencing a demographic transition. Heart failure and other cardiac problems are more likely to develop in older adults. As seniors are more likely to need cardiac resynchronization therapy, India's aging population expands the patient pool for CRT devices. The aging population is a major factor in the expansion of the CRT market.

India Cardiac Resynchronization Therapy (crt) Market Restraints

high Cost of Device

The demand for CRT devices is anticipated to be constrained by their high cost, particularly in developing and undeveloped economies. These gadgets are priced differently depending on the brand. Devices that are MRI-compatible cost more than those that are not.

Further restricting the market is that governments in many developing nations, including India, do not offer price caps on these gadgets. In India, a CRT-D implant costs roughly USD 16,500 on average. Depending on the facility and surgeon, this cost can range from USD 7,000 to USD 25,000.

This price is greater than the price range of USD 650 to USD 2,600 for automatic external defibrillators. In a similar vein, pacemakers cost between USD 3,000 and USD 4,000.

Therefore, the high price of CRT is expected to have a detrimental effect on the market.

India Cardiac Resynchronization Therapy (crt) Market Opportunities

Government Initiatives

The Indian government has invested in constructing hospitals, clinics, and cardiac care facilities. These programs seek to increase accessibility to high-quality healthcare services, including cutting-edge cardiac therapies like CRT. Expanding the healthcare infrastructure makes the adoption of CRT equipment and processes possible.

The Indian government is key in encouraging patient access to CRT through its health insurance programs and payment rules. Public health insurance programs for qualifying patients, including Ayushman Bharat and state-specific health insurance plans, cover particular cardiac operations and equipment, including CRT. These reimbursement procedures promote CRT use and lower patient costs, resulting in market expansion.

Segmental Analysis

The India cardiac resynchronization therapy (CRT) market is segmented based on Product, End-User.

Based on OS, the Indian market is segmented by CRT-D and CRT-P.

CRT-D dominated the market over the forecast period.

Based on End-User, the Indian market is segmented by Hospitals, Cardiac Centre.

Hospitals dominated the market over the forecast period.

Regional Analysis of the Cardiac Resynchronization Therapy (CRT) Market

According to a study that was published in the Indian Heart Journal in December 2018, only 116 out of 471 heart failure patients (24.6%) chose to have a CRT device implanted because of economic reasons. After two years, it was discovered that patients who received CRT had better clinical outcomes. Over the forecast period, rising disposable income, expanding healthcare infrastructure, and rising cardiac health awareness are expected to drive the market. International competitors are also growing their operations to take market share in the nation. Abbott supported its growth goals by introducing a new portfolio of CRT-Ds and ICDs in India in October 2020.

India Cardiac Resynchronization Therapy (CRT) Market Size By Segments

Request Customizationto receive a tailored report.

India Cardiac Resynchronization Therapy (CRT) Market Share By Segments

Speak to an Analystto discuss market opportunities.

List of Key and Emerging Players in India Cardiac Resynchronization Therapy (CRT) Market

  • Abbott
  • Boston Scientific Corporation
  • Medtronic
  • Biotronik SE & Co. Kg
  • Microport Scientific Corporation
  • LivaNova PLC
  • Medico S.R.L.

Key Industry Developments

  • June 2026: Medtronic expanded its cardiac rhythm management portfolio in India by advancing next-generation Cardiac Resynchronization Therapy (CRT) devices featuring enhanced remote monitoring, longer battery life, and AI-enabled diagnostics. The company focused on improving outcomes for patients with heart failure.
  • May 2026: Abbott expanded its electrophysiology and cardiac rhythm management portfolio by introducing advanced CRT-P and CRT-D systems with improved lead technology and integrated remote patient monitoring capabilities for healthcare providers across India.
  • April 2026: Boston Scientific expanded its cardiac rhythm management solutions by advancing MRI-compatible CRT devices with enhanced arrhythmia detection, adaptive pacing technologies, and digital patient management features.
  • January 2026: BIOTRONIK expanded its cardiac rhythm management portfolio in India by introducing advanced CRT systems with remote monitoring capabilities and intelligent pacing algorithms designed to improve heart failure management.

Report Scope

Market Metric Details & Data (2025-2034)
Market Size in 2025 USD 306 Million
Market Size in 2026 USD 336.97 Million
Market Size in 2034 USD 728.65 Million
CAGR 10.12% (2026-2034)
Base Year for Estimation 2025
Historical Data2022-2024
Forecast Period2026-2034
Study Period 2022-2034
Key Market Players Abbott, Boston Scientific Corporation, Medtronic, Biotronik SE & Co. Kg, Microport Scientific Corporation
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered By Product, By End User

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

How big is the cardiac resynchronization therapy market?
The Indian cardiac resynchronization therapy market witnessed significant growth in the past and is expected to grow at a CAGR of 10.12% during the forecast period (2026-2034).
Key verticals adopting the cardiac resynchronization therapy market include: Abbott, Boston Scientific Corporation, Medtronic, Biotronik SE & Co. Kg, Microport Scientific Corporation, LivaNova PLC, Medico S.R.L.
High prevalence of cardiac diseases and increasing aging population is the key driver for the growth of the cardiac resynchronization therapy market.
Government initiatives is one of the upcoming key trends in the cardiac resynchronization therapy market.

Author's Details


Debashree Bora

Healthcare Lead

 Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.

Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.

With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.

A PHP Error was encountered

Severity: Notice

Message: Undefined variable: relatedReports

Filename: reportpages/rd.php

Line Number: 640

Backtrace:

File: /var/www/html/application/views/frontend/reportpages/rd.php
Line: 640
Function: _error_handler

File: /var/www/html/application/controllers/FrontendRegionalReportController.php
Line: 108
Function: view

File: /var/www/html/index.php
Line: 364
Function: require_once

Report Details
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
custom reports
Need a Tailored Report?
80% of our existing clients ask for tailored reports.
Request Customization
Request Sample Order Report Now

We are featured on: